Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Enanta Pharmaceuticals ( (ENTA) ) has shared an announcement.
On August 20, 2025, Enanta Pharmaceuticals announced it filed a patent infringement lawsuit against Pfizer Inc. in the Unified Patent Court of the European Union. The suit seeks to determine liability for the use and infringement of Enanta’s European Patent No. EP 4 051 265 in relation to Pfizer’s COVID-19 antiviral, Paxlovid™, across 18 EU countries. This legal action follows the recent grant of the patent by the European Patent Office and parallels ongoing U.S. litigation concerning a related patent. The outcome of this case could significantly impact Enanta’s market position and financial performance, as well as influence its reputation and stock market valuation.
The most recent analyst rating on (ENTA) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Enanta Pharmaceuticals stock, see the ENTA Stock Forecast page.
Spark’s Take on ENTA Stock
According to Spark, TipRanks’ AI Analyst, ENTA is a Neutral.
Enanta Pharmaceuticals’ overall stock score is primarily impacted by its financial performance challenges, including declining revenue and negative profitability. Technical analysis provides some short-term positive signals, but the valuation remains unattractive due to negative earnings. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on ENTA stock, click here.
More about Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel small molecule drugs for viral infections and immunological diseases. The company is known for its work in virology and immunology, with clinical programs targeting respiratory syncytial virus (RSV) and an immunology pipeline aimed at inflammatory diseases. Enanta also collaborates with AbbVie on hepatitis C virus (HCV) treatments, contributing to its operational funding.
Average Trading Volume: 170,670
Technical Sentiment Signal: Sell
Current Market Cap: $174.7M
For an in-depth examination of ENTA stock, go to TipRanks’ Overview page.